Welcome to LookChem.com Sign In|Join Free
  • or
2-Butanone, 1-amino-3-methyl-, hydrochloride is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

21419-25-0

Post Buying Request

21419-25-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

21419-25-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 21419-25-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,4,1 and 9 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 21419-25:
(7*2)+(6*1)+(5*4)+(4*1)+(3*9)+(2*2)+(1*5)=80
80 % 10 = 0
So 21419-25-0 is a valid CAS Registry Number.

21419-25-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-amino-3-methylbutan-2-one,hydrochloride

1.2 Other means of identification

Product number -
Other names 2-Butanone,1-amino-3-methyl-,hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:21419-25-0 SDS

21419-25-0Relevant academic research and scientific papers

HEPATITIS B CAPSID ASSEMBLY MODULATORS

-

Paragraph 00171; 00172; 00282; 00283, (2021/06/22)

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

-

Page/Page column 155, (2021/05/21)

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

Rearrangement of N-tert-butanesulfinyl α-halo imines with alkoxides to N-tert-butanesulfinyl 2-amino acetals as precursors of N-protected and N-unprotected α-amino carbonyl compounds

Colpaert, Filip,Mangelinckx, Sven,Denolf, Bram,De Kimpe, Norbert

experimental part, p. 6023 - 6032 (2012/10/08)

Reaction of N-tert-butanesulfinyl α-halo imines with alkoxides afforded new N-tert-butanesulfinyl 2-amino acetals in good to excellent yield. These N-tert-butanesulfinyl 2-amino acetals are convenient precursors for the TMSOTf-promoted synthesis of the co

IMIDAZOLE CARBONYL COMPOUND

-

Page/Page column 59, (2010/09/17)

To develop an antibiotic having a novel mechanism of action, the present inventors have searched for a compound that has weak cytotoxicity, the physical property of high solubility in water, the effect of inhibiting both DNA gyrase GyrB and topoisomerase IV ParE subunits, and sufficient antibacterial activity. As a result, the present inventors have completed the present invention by finding that a compound of the present invention represented by the general formula (1), a pharmacologically acceptable salt thereof, and a prodrug thereof have desirable properties. The present invention provides a pharmaceutical composition (particularly, a preventive or therapeutic composition for infectious disease) comprising a compound represented by the formula (1), a pharmacologically acceptable salt thereof, or a prodrug thereof as an active ingredient.

Pyrrole derivatives

-

, (2008/06/13)

Disclosed are novel pyrrole derivatives, a process for their manufacture, pharmaceutical compositions containing such compounds and the use of such compounds in the treatment of HIV mediated diseases.

Alkyloxazolylacetic acid derivative for the treatment of hyperlipidemia

-

, (2008/06/13)

A alkyloxazolylacetic acid derivative of the formula: STR1 wherein Ring A is phenyl or halogenophenyl, R1 is lower alkyl of one to 5 carbon atoms and R2 is hydrogen or lower alkyl of one to 3 carbon atoms. The compound (I) is useful

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 21419-25-0